Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 24, 2025; 16(10): 112097
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.112097
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.112097
Overcoming chemoresistance in non-small cell lung cancer: Insights into the influence of inflammatory factors on treatment response
Yue Dai, Nian Cao, Xiu-Wen Tian, Juan Feng, Zhen-Zhen Hu, Jian-Qiang Xu, Department of Pulmonary and Critical Care Medicine, The Third Clinical Medical College of the Three Gorges University, Gezhouba Central Hospital of Sinopharm, Yichang 443002, Hubei Province, China
Ya-Yun Liu, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, China Three Gorges University, Yichang 443002, Hubei Province, China
Co-corresponding authors: Ya-Yun Liu and Jian-Qiang Xu.
Author contributions: Xu JQ and Liu YY contribute equally to this study as co-corresponding authors; Xu JQ, Liu YY and Dai Y conceptualized and designed the study, drafted the initial manuscript; Cao N, Tian XW, Feng Jand Hu ZZ collected the data and carried out the initial analyses; Xu JQ, Liu YY and Dai Y critically reviewed the manuscript for important intellectual content; all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Institutional review board statement: This study was approved by the Ethics Committee of Gezhouba Central Hospital of Sinopharm and conducted in accordance with the approval guidelines. All patients voluntarily signed the informed consent form. The study was conducted in accordance with the Declaration of Helsinki.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Data sharing statement: The data used to support the findings of this study are available from the corresponding author upon request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian-Qiang Xu, MD, Department of Pulmonary and Critical Care Medicine, The Third Clinical Medical College of the Three Gorges University, Gezhouba Central Hospital of Sinopharm, No. 60 Qiao Hu Road, Xiling District, Yichang 443002, China.
Received: July 18, 2025
Revised: July 31, 2025
Accepted: September 2, 2025
Published online: October 24, 2025
Processing time: 99 Days and 3.6 Hours
Revised: July 31, 2025
Accepted: September 2, 2025
Published online: October 24, 2025
Processing time: 99 Days and 3.6 Hours
Core Tip
Core Tip: This study explores the association between inflammatory cytokines and cisplatin (DDP) resistance in non-small cell lung cancer (NSCLC). Elevated levels of interleukin (IL)-6, IL-8, and tumor necrosis factor-α were detected in DDP-resistant tissues and cells. Notably, inhibition of IL-6 using the receptor antagonist tocilizumab restored DDP sensitivity by reducing cell viability, migration, and invasion, while enhancing apoptosis. These findings underscore IL-6 as a promising therapeutic target to overcome DDP resistance in NSCLC.